Incyte Genomics INCY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Incyte Genomics (INCY) Core Market Data and Business Metrics
Latest Closing Price
$60.91Price-Earnings Ratio
320.58Total Outstanding Shares
193.52 Million SharesDividend
No dividendSIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
NASDAQHeadquarters
1801 Augustine Cut-off, Wilmington, DE, 19803
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,592,257 Shares | 3.99 | 3/14/2025 | 6,359,808 Shares |
| 1,457,920 Shares | 4.01 | 2/28/2025 | 5,846,755 Shares |
| 2,138,776 Shares | 3.89 | 2/14/2025 | 8,323,615 Shares |
| 1,203,035 Shares | 4.81 | 1/31/2025 | 5,788,151 Shares |
| 1,569,313 Shares | 3.21 | 1/15/2025 | 5,038,309 Shares |
| 1,902,917 Shares | 2.68 | 12/31/2024 | 5,103,263 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $101.85 Million |
| Exchange Gains/Losses | $-7.84 Million |
| Net Cash Flow From Operating Activities | $101.85 Million |
| Net Cash Flow | $-1.92 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-2.04 Billion |
| Net Cash Flow From Financing Activities | $-2.04 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $32.48 Million |
| Operating Income/Loss | $-52.88 Million |
| Benefits Costs and Expenses | $3.80 Billion |
| Operating Expenses | $3.84 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income Tax Expense/Benefit | $241.38 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $-7.24 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $25.24 Million |
| Comprehensive Income/Loss Attributable To Parent | $25.24 Million |
| Other Comprehensive Income/Loss | $99.22 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $3.17 Billion |
| Other Non-current Assets | $1.43 Billion |
| Liabilities And Equity | $5.01 Billion |
| Inventory | $70.44 Million |
| Noncurrent Assets | $2.20 Billion |
| Equity | $3.17 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||